Neurocrine Biosciences, Inc. (NBIX)

Precedente Chiudi:

$137.76

Aprire:

$137.47

Volume 24 ore:

716.42K

Capitalizzazione di mercato:

$13.68B

Reddito:

$1.89B

Utile/perdita netta:

$249.70M

Rapporto P/E:

73.11

EPS:

1.86

Flusso di cassa netto:

$361.60M

1 W Prestazione:

+3.02%

1M Prestazione:

-3.66%

6M Prestazione:

+26.01%

1 anno Prestazione:

+32.39%

Intervallo 1D:

$135.17

$138.63

Portata 52W:

$89.04

$148.37

Neurocrine Biosciences, Inc. Stock (NBIX) Company Profile

Nome

Neurocrine Biosciences, Inc.

Settore

Healthcare (1191)

Industria

Drug Manufacturers - Specialty & Generic (4)

Telefono

858-617-7600

Indirizzo

12780 El Camino Real, San Diego, CA

Dipendente

574

Cinguettio

Prossima data di guadagno

2024-05-22

Ultimi documenti SEC

NBIX's Discussions on Twitter

Neurocrine Biosciences, Inc. Stock (NBIX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-13	Ripresa	Citigroup	Neutral
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-08-21	Reiterato	Mizuho	Neutral
2023-07-24	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-07-06	Aggiornamento	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-30	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-03-03	Aggiornamento	Evercore ISI	In-line → Outperform
2023-02-03	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Downgrade	Evercore ISI	Outperform → In-line
2022-10-11	Iniziato	UBS	Buy
2022-09-26	Iniziato	Wells Fargo	Equal Weight
2022-06-06	Ripresa	Jefferies	Buy
2022-03-03	Downgrade	Piper Sandler	Overweight → Neutral
2022-02-25	Aggiornamento	Goldman	Neutral → Buy
2022-01-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Iniziato	BMO Capital Markets	Underperform
2021-11-17	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-08-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-05-18	Ripresa	Goldman	Neutral
2021-05-06	Aggiornamento	Barclays	Equal Weight → Overweight
2021-02-02	Iniziato	Raymond James	Outperform
2020-09-30	Iniziato	The Benchmark Company	Hold
2020-08-04	Downgrade	JP Morgan	Overweight → Neutral
2020-06-29	Downgrade	Goldman	Buy → Neutral
2020-06-09	Iniziato	Wedbush	Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-27	Iniziato	Barclays	Equal Weight
2020-02-24	Iniziato	William Blair	Outperform
2020-02-06	Iniziato	Mizuho	Neutral
2020-02-05	Reiterato	H.C. Wainwright	Buy
2019-12-13	Downgrade	Credit Suisse	Outperform → Neutral
2019-08-07	Iniziato	RBC Capital Mkts	Outperform
2019-07-16	Iniziato	Oppenheimer	Outperform
2019-06-05	Iniziato	Guggenheim	Neutral
2019-05-21	Iniziato	Credit Suisse	Outperform
2019-04-22	Aggiornamento	JP Morgan	Neutral → Overweight
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-02-06	Reiterato	BofA/Merrill	Buy
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-12-13	Iniziato	Goldman	Buy
2018-11-21	Iniziato	Canaccord Genuity	Buy

Mostra tutto

Neurocrine Biosciences, Inc. Borsa (NBIX) Ultime notizie

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Zacks Investment Research

Where Neurocrine Biosciences Stands With Analysts

Benzinga

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

Benzinga

In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences

Benzinga

Decoding 8 Analyst Evaluations For Neurocrine Biosciences

Benzinga

Neurocrine Biosciences, Inc. Azioni (NBIX) Dati Finanziari

Neurocrine Biosciences, Inc. (NBIX) Reddito 2024

Neurocrine Biosciences, Inc. (NBIX) Reddito netto 2024

Neurocrine Biosciences, Inc. (NBIX) Flusso di cassa 2024

Neurocrine Biosciences, Inc. (NBIX) Utile per azione 2024

Neurocrine Biosciences, Inc. Azioni (NBIX) insider trading